1.Davis BH, Limdi NA. Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine. Clinical pharmacology and therapeutics. 2021;110(4):909-25.
2.Gummadi AC, Guddati AK. Genetic Polymorphisms in Pharmaceuticals and Chemotherapy. World journal of oncology. 2021;12(5):149-54.
3.Behdani AM, Lai J, Kim C, Basalelah L, Halsey T, Donohoe KL, et al. Optimizing pharmacogenomic decision-making by data science. PLOS digital health. 2024;3(2):e0000451.
4.Tyson RJ, Park CC, Powell JR, Patterson JH, Weiner D, Watkins PB, et al. Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Frontiers in pharmacology. 2020;11:420.
5.Su J, Yang L, Sun Z, Zhan X. Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. Molecular & Cellular Proteomics. 2024;23(3):100737.
6.Hossam Abdelmonem B, Abdelaal NM, Anwer EKE, Rashwan AA, Hussein MA, Ahmed YF, et al. Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review. Biomedicines [Internet]. 2024; 12(7).
7.Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: Driving Personalized Medicine. Pharmacological reviews. 2023;75(4):789-814.
8.Qahwaji R, Ashankyty I, Sannan NS, Hazzazi MS, Basabrain AA, Mobashir M. Pharmacogenomics: A Genetic Approach to Drug Development and Therapy. Pharmaceuticals [Internet]. 2024; 17(7).
9.Javaid M, Haleem A, Singh RP. Health informatics to enhance the healthcare industry’s culture: An extensive analysis of its features, contributions, applications and limitations. Informatics and Health. 2024;1(2):123-48.
10.Qahwaji R, Ashankyty I, Sannan NS, Hazzazi MS, Basabrain AA, Mobashir M. Pharmacogenomics: A Genetic Approach to Drug Development and Therapy. Pharmaceuticals (Basel, Switzerland). 2024;17(7).
11.Shea L, Pesa J, Geonnotti G, Powell V, Kahn C, Peters W. Improving diversity in study participation: Patient perspectives on barriers, racial differences and the role of communities. Health expectations : an international journal of public participation in health care and health policy. 2022;25(4):1979-87.
12.Micaglio E, Locati ET, Monasky MM, Romani F, Heilbron F, Pappone C. Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine. Frontiers in pharmacology. 2021;12:651720.
13.Su J, Yang L, Sun Z, Zhan X. Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. Molecular & cellular proteomics : MCP. 2024;23(3):100737.
14.Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, et al. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics [Internet]. 2024; 16(3).
15.Raijada D, Wac K, Greisen E, Rantanen J, Genina N. Integration of personalized drug delivery systems into digital health. Advanced Drug Delivery Reviews. 2021;176:113857.
16.Ahsani-Estahbanati E, Sergeevich Gordeev V, Doshmangir L. Interventions to reduce the incidence of medical error and its financial burden in health care systems: A systematic review of systematic reviews. 2022;9.
17.Abad-Santos F, Aliño SF, Borobia AM, García-Martín E, Gassó P, Maroñas O, et al. Developments in pharmacogenetics, pharmacogenomics, and personalized medicine. Pharmacological Research. 2024;200:107061.
18.Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta pharmaceutica Sinica B. 2022;12(7):3049-62.
19.Hippman C, Nislow C. Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges. Journal of personalized medicine. 2019;9(3).
20.Duan X-P, Qin B-D, Jiao X-D, Liu K, Wang Z, Zang Y-S. New clinical trial design in precision medicine: discovery, development and direction. Signal Transduction and Targeted Therapy. 2024;9(1):57.
21.Marcu LG, Marcu DC. Pharmacogenomics and Big Data in medical oncology: developments and challenges. Therapeutic advances in medical oncology. 2024;16:17588359241287658.
22.Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. Cancers [Internet]. 2024; 16(13).
23.Kabbani D, Akika R, Wahid A, Daly AK, Cascorbi I, Zgheib NK. Pharmacogenomics in practice: a review and implementation guide. 2023;14.
24.Kabbani D, Akika R, Wahid A, Daly AK, Cascorbi I, Zgheib NK. Pharmacogenomics in practice: a review and implementation guide. Frontiers in pharmacology. 2023;14:1189976.
25.Omran S, Leong SL, Blebil A, Mohan D, Teoh SL. Effectiveness of pharmacogenomics educational interventions on healthcare professionals and health professions students: A systematic review. Research in Social and Administrative Pharmacy. 2023;19(11):1399-411.
26.Kloypan C, Koomdee N, Satapornpong P, Tempark T, Biswas M, Sukasem C. A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine. Pharmaceuticals [Internet]. 2021; 14(11).
27.Scott SA. Personalizing medicine with clinical pharmacogenetics. Genetics in Medicine. 2011;13(12):987-95.
28.Jmel H, Sarno S, Giuliani C, Boukhalfa W, Abdelhak S, Luiselli D, et al. Genetic diversity of variants involved in drug response among Tunisian and Italian populations toward personalized medicine. Scientific Reports. 2024;14(1):5842.
29.Kaye AD, Koress CM, Novitch MB, Jung JW, Urits I, Viswanath O, et al. Pharmacogenomics, concepts for the future of perioperative medicine and pain management: A review. Best Practice & Research Clinical Anaesthesiology. 2020;34(3):651-62.
30.Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, et al. Current trends in drug metabolism and pharmacokinetics. Acta pharmaceutica Sinica B. 2019;9(6):1113-44.
31.Amaro-Álvarez L, Cordero-Ramos J, Calleja-Hernández M. Exploring the impact of pharmacogenetics on personalized medicine: A systematic review. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2024;48(6):299-309.
32.Bansal N, Momin S, Bansal R, Gurram Venkata SKR, Ruser L, Yusuf KJPM. Pharmacokinetics of drugs: newborn perspective. 2023. 2023;7.
33.Galeano D, Li S, Gerstein M, Paccanaro A. Predicting the frequencies of drug side effects. Nature Communications. 2020;11(1):4575.
34.Iacopetta D, Ceramella J, Catalano A, Scali E, Scumaci D, Pellegrino M, et al. Impact of Cytochrome P450 Enzymes on the Phase I Metabolism of Drugs. Applied Sciences [Internet]. 2023; 13(10).
35.Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. International journal of molecular sciences. 2021;22(23).
36.Gopisankar MG. CYP2D6 pharmacogenomics. Egyptian Journal of Medical Human Genetics. 2017;18(4):309-13.
37.Vaidya F, Chhipa A, Mishra V, Gupta V, Rawat S, Kumar A, et al. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Reports. 2020;5.
38.Nahid NA, Johnson JA. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine. Expert opinion on drug metabolism & toxicology. 2022;18(11):769-85.
39.Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics. 2013;138(1):103-41.
40.He W, Grassmann F, Eriksson M, Eliasson E, Margolin S, Thorén L, et al. CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020;38(6):548-57.
41.Hines LJ, Wilke RA, Myers R, Mathews CA, Liu M, Baye JF, et al. Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression. Clinical and Translational Science. 2024;17(6):e13822.
42.Ellithi M, Baye J, Wilke RA. CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls. Pharmacogenomics. 2020;21(12):889-97.
43.Mirabbasi SA, Khalighi K, Wu Y, Walker S, Khalighi B, Fan W, et al. CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic. Journal of community hospital internal medicine perspectives. 2017;7(3):151-6.
44.Shubbar Q, Alchakee A, Issa KW, Adi AJ, Shorbagi AI, Saber-Ayad M. From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. 2024;15.
45.Squizzato A, Bellesini M, Takeda A, Middeldorp S, Donadini MP. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. The Cochrane database of systematic reviews. 2017;12(12):Cd005158.
46.Lee CR, Thomas CD, Beitelshees AL, Tuteja S, Empey PE, Lee JC, et al. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clinical pharmacology and therapeutics. 2021;109(3):705-15.
47.Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, et al. Clopidogrel Pharmacogenetics. Circulation Cardiovascular interventions. 2019;12(4):e007811.
48.Shubbar Q, Alchakee A, Issa KW, Adi AJ, Shorbagi AI, Saber-Ayad M. From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. Frontiers in pharmacology. 2024;15:1326776.
49.Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S-e88S.
50.Tatarunas V, Lesauskaite V, Veikutiene A, Grybauskas P, Jakuska P, Jankauskiene L, et al. The effect of CYP2C9, VKORC1 and CYP4F2 polymorphism and of clinical factors on warfarin dosage during initiation and long-term treatment after heart valve surgery. Journal of thrombosis and thrombolysis. 2014;37(2):177-85.
51.Zhou X-Y, Lu X-R, Li Y-H, Ma Y-Q, Zhao S-W, Wang F, et al. Identification and Enzymatic Activity Evaluation of a Novel CYP2C9 Allelic Variant Discovered in a Patient. 2021;12.
52.Shaw K, Amstutz U, Kim R, Lesko L, Turgeon J, Michaud V, et al. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Therapeutic drug monitoring. 2015;37:428-36.
53.Azzam H, Elwakeel H, Awad I, El-farahaty R, El-Gilany A-H, El-Sharawy S. VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2014;27.
54.Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. Genomics, proteomics & bioinformatics. 2016;14(5):298-313.
55.Kolou M, Poda A, Diallo Z, Konou E, Dokpomiwa T, Zoungrana J, et al. Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa. BMC Immunology. 2021;22(1):48.
56.Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Seminars in cancer biology. 2020;61:167-79.
57.Hossam Abdelmonem B, Abdelaal NM, Anwer EKE, Rashwan AA, Hussein MA, Ahmed YF, et al. Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review. Biomedicines. 2024;12(7).
58.Khan BA, Robinson R, Fohner AE, Muzquiz LI, Schilling BD, Beans JA, et al. Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People. Clinical and translational science. 2018;11(3):312-21.
59.Mulder TAM, de With M, Del Re M, Danesi R, Mathijssen RHJ, van Schaik RHN. Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. Cancers. 2021;13(4).
60.Lopez J, Mark J, Duarte GJ, Shaban M, Sosa F, Mishra R, et al. Role of genetic polymorphisms in clopidogrel response variability: a systematic review. Open heart. 2023;10(2).
61.Deshpande P, Hertzman RJ, Palubinsky AM, Giles JB, Karnes JH, Gibson A, et al. Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions. Clinical pharmacology and therapeutics. 2021;110(3):607-15.
62.Kazaoka A, Fujimori S, Yamada Y, Shirayanagi T, Gao Y, Kuwahara S, et al. HLA-B*57:01-dependent intracellular stress in keratinocytes triggers dermal hypersensitivity reactions to abacavir. PNAS nexus. 2024;3(4):pgae140.
63.Molatefi R, Talebi S, Samei A, Roshanravan N, Manshouri S, Hashemi B, et al. Clues of HLAs, metabolic SNPs, and epigenetic factors in T cell-mediated drug hypersensitivity reactions. Heliyon. 2024;10(14):e33976.
64.    Shalia K, Doshi S, Parikh S, Pawar P, Divekar S, Varma S, et al. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response. The Journal of the Association of Physicians of India. 2012;60:34-8.
65.Shugg T, Tillman EM, Breman AM, Hodge JC, McDonald CA, Ly RC, et al. Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned. Clinical Pharmacology & Therapeutics. 2024;116(4):914-31.
66.Mauriello A, Ascrizzi A, Molinari R, Falco L, Caturano A, D’Andrea A, et al. Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk. Genes. 2023;14(11).
67.Sentana-Lledo D, Academia E, Viray H, Rangachari D, Kobayashi SS, VanderLaan PA, et al. EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates. 2023. 2023;12(7):1590-610.
68.Weth FR, Hoggarth GB, Weth AF, Paterson E, White MPJ, Tan ST, et al. Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. British Journal of Cancer. 2024;130(5):703-15.
69.Alchakee A, Ahmed M, Eldohaji L, Alhaj H, Saber-Ayad M. Pharmacogenomics in Psychiatry Practice: The Value and the Challenges. International journal of molecular sciences. 2022;23(21).
70.Floris M, Moschella A, Alcalay M, Montella A, Tirelli M, Fontana L, et al. Pharmacogenetics in Italy: current landscape and future prospects. Human Genomics. 2024;18(1):78.
71.Stratton TP, Olson AW. Personalizing Personalized Medicine: The Confluence of Pharmacogenomics, a Person’s Medication Experience and Ethics. Pharmacy [Internet]. 2023; 11(3).
72.Buchanan J, Wordsworth S, Schuh A. Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics. 2013;14(15):1833-47.
73.Oates JT, Lopez D. Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application. International journal of biomedical investigation. 2018;1(2).